within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XG01_Bortezomib;
model Bortezomib 
   extends Pharmacolibrary.Drugs.ATC.L.L01XG01;

  annotation(Documentation(
    info ="<html><body><p>Bortezomib is a reversible proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. It is administered parenterally and is FDA-approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Healthy adult patients and patients with multiple myeloma, intravenous bolus administration.</p><h4>References</h4><ol><li><p>Tan, CRC, et al., &amp; Barta, SK (2019). Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib. <i>Clinical pharmacokinetics</i> 58(2) 157–168. DOI:<a href=&quot;https://doi.org/10.1007/s40262-018-0679-9&quot;>10.1007/s40262-018-0679-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29802543/&quot;>https://pubmed.ncbi.nlm.nih.gov/29802543</a></p></li><li><p>Barta, SK, et al., &amp; Braunschweig, I (2017). Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. <i>Clinical lymphoma, myeloma &amp; leukemia</i> 17(10) 650–657. DOI:<a href=&quot;https://doi.org/10.1016/j.clml.2017.06.005&quot;>10.1016/j.clml.2017.06.005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28684379/&quot;>https://pubmed.ncbi.nlm.nih.gov/28684379</a></p></li><li><p>Leveque, D (2014). Subcutaneous administration of anticancer agents. <i>Anticancer research</i> 34(4) 1579–1586. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24692685/&quot;>https://pubmed.ncbi.nlm.nih.gov/24692685</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Bortezomib;
